JP7479287B2 - 超高速応答を伴うグルコース誘発性インスリン送達のための電荷切り替え可能な高分子デポ - Google Patents

超高速応答を伴うグルコース誘発性インスリン送達のための電荷切り替え可能な高分子デポ Download PDF

Info

Publication number
JP7479287B2
JP7479287B2 JP2020545067A JP2020545067A JP7479287B2 JP 7479287 B2 JP7479287 B2 JP 7479287B2 JP 2020545067 A JP2020545067 A JP 2020545067A JP 2020545067 A JP2020545067 A JP 2020545067A JP 7479287 B2 JP7479287 B2 JP 7479287B2
Authority
JP
Japan
Prior art keywords
insulin
glucose
polymer
group
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020545067A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021504448A5 (enExample
JP2021504448A (ja
Inventor
グ ゼン
ワン ジンキアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
North Carolina State University
Original Assignee
North Carolina State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North Carolina State University filed Critical North Carolina State University
Publication of JP2021504448A publication Critical patent/JP2021504448A/ja
Publication of JP2021504448A5 publication Critical patent/JP2021504448A5/ja
Application granted granted Critical
Publication of JP7479287B2 publication Critical patent/JP7479287B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2020545067A 2017-11-21 2018-11-20 超高速応答を伴うグルコース誘発性インスリン送達のための電荷切り替え可能な高分子デポ Active JP7479287B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762589091P 2017-11-21 2017-11-21
US62/589,091 2017-11-21
PCT/US2018/061953 WO2019104006A1 (en) 2017-11-21 2018-11-20 Charge-switchable polymeric depot for glucose-triggered insulin delivery with ultrafast response

Publications (3)

Publication Number Publication Date
JP2021504448A JP2021504448A (ja) 2021-02-15
JP2021504448A5 JP2021504448A5 (enExample) 2022-01-04
JP7479287B2 true JP7479287B2 (ja) 2024-05-08

Family

ID=66632129

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020545067A Active JP7479287B2 (ja) 2017-11-21 2018-11-20 超高速応答を伴うグルコース誘発性インスリン送達のための電荷切り替え可能な高分子デポ

Country Status (6)

Country Link
US (1) US11813352B2 (enExample)
EP (1) EP3713594A4 (enExample)
JP (1) JP7479287B2 (enExample)
CN (1) CN111629746B (enExample)
MA (1) MA50815A (enExample)
WO (1) WO2019104006A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165294A1 (en) 2017-03-07 2018-09-13 North Carolina State University Insulin-responsive glucagon delivery patch
WO2019104006A1 (en) 2017-11-21 2019-05-31 North Carolina State University Charge-switchable polymeric depot for glucose-triggered insulin delivery with ultrafast response
CN112842333A (zh) * 2020-12-31 2021-05-28 华中科技大学 一种可视化葡萄糖浓度检测微针贴片、制备方法及应用
CN113197838B (zh) * 2021-03-31 2022-08-23 浙江大学 一种无酶糖敏微针贴及其温和制备方法
WO2024026280A1 (en) * 2022-07-26 2024-02-01 University Of Notre Dame Du Lac Polymeric microneedle arrays crosslinked by pba-diol complexes for glucose-responsive insulin delivery
CN118949061A (zh) * 2023-08-07 2024-11-15 浙江大学 一种糖响应鱼精蛋白胰岛素及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101273961A (zh) 2007-03-30 2008-10-01 中国人民解放军总医院 葡萄糖敏感水凝胶
JP2016209372A (ja) 2015-05-11 2016-12-15 国立大学法人 東京医科歯科大学 インスリン送達用デバイス
WO2017069282A1 (ja) 2015-10-23 2017-04-27 国立大学法人東京医科歯科大学 薬剤送達用デバイス

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8137697B1 (en) 2004-10-05 2012-03-20 Gp Medical, Inc. Nanoparticles for protein/peptide delivery and delivery means thereof
US9101547B2 (en) 2011-08-04 2015-08-11 Nano And Advanced Materials Institute Limited Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery
EP2991673A4 (en) 2013-04-30 2016-12-21 Massachusetts Inst Technology INJECTABLE NANON NETWORKS FOR DIABETES TREATMENT
SG11201708509YA (en) * 2015-04-21 2017-11-29 Univ North Carolina State Glucose-responsive insulin delivery system using hyoxia-sensitive nanocomposites
CN104811694B (zh) * 2015-04-28 2017-03-08 华为技术有限公司 一种视频数据质量评估的方法和装置
WO2019104006A1 (en) 2017-11-21 2019-05-31 North Carolina State University Charge-switchable polymeric depot for glucose-triggered insulin delivery with ultrafast response

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101273961A (zh) 2007-03-30 2008-10-01 中国人民解放军总医院 葡萄糖敏感水凝胶
JP2016209372A (ja) 2015-05-11 2016-12-15 国立大学法人 東京医科歯科大学 インスリン送達用デバイス
WO2017069282A1 (ja) 2015-10-23 2017-04-27 国立大学法人東京医科歯科大学 薬剤送達用デバイス

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Shiino, D. et al.，Amine containing phenylboronic acid gel for glucose-responsive insulin release under physiological pH，Journal of Controlled Release，1995年，Vol.37, No.3，p.269-276，doi:10.1016/0168-3659(95)00084-4
Veiseh, O., Langer, R.，Diabetes: A smart insulin patch，Nature，2015年，Vol.524, No.7563，p.39-40，doi:10.1038/524039a
Wu, Z. et al.，Phenylboronic acid grafted chitosan as a glucose-sensitive vehicle for controlled insulin release，Journal of pharmaceutical sciences，2011年，Vol.100, No.6，p.2278-2286，doi:10.1002/jps.22463

Also Published As

Publication number Publication date
EP3713594A4 (en) 2021-11-03
US11813352B2 (en) 2023-11-14
CN111629746A (zh) 2020-09-04
MA50815A (fr) 2020-09-30
US20200360269A1 (en) 2020-11-19
WO2019104006A1 (en) 2019-05-31
EP3713594A1 (en) 2020-09-30
CN111629746B (zh) 2024-04-16
JP2021504448A (ja) 2021-02-15

Similar Documents

Publication Publication Date Title
JP7479287B2 (ja) 超高速応答を伴うグルコース誘発性インスリン送達のための電荷切り替え可能な高分子デポ
US20220160841A1 (en) Glucose-responsive insulin delivery microneedle system
US11351230B2 (en) Patch loaded with dual-sensitive vesicles for enhanced glucose-responsive insulin delivery
EP2814461B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide substitue
US11850285B2 (en) Insulin-responsive glucagon delivery patch
US20160067190A1 (en) Injectable nano-network gels for diabetes treatment
FR2985428A1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue
FR2985429A1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle
US12161749B2 (en) Microneedle-array patches with glucose-responsive matrix for closed-loop insulin delivery
WO2008135561A1 (fr) Particules a base de polyelectrolytes et de principe actif a liberation modifiee et formulations pharmaceutiques contenant ces particules
US20200246321A1 (en) Locally-induced adipose tissue browning by microneedle patch for obesity treatment
HK1245105B (en) Glucose-responsive insulin delivery system using hypoxia-sensitive nanocomposites

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230110

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230227

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230612

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240409

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240423

R150 Certificate of patent or registration of utility model

Ref document number: 7479287

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150